NASDAQ · Biotechnology · USD

Kardigan, Inc. (KARD) Stock Analysis

Kardigan, Inc. (KARD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KARD

$20.85

+$0.11 (+0.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KARD with… →

KARD Key Statistics

As of Sep 4, 2026

Trading

Open: $21.00
Previous Close: $20.74
Day's Range: 20.50–21.41
52-Week Range: 16.25–27.00
Volume: 279.62K

Valuation

Market Cap: $1.95B
P/E Ratio: unprofitable
EPS (ttm): −3.09

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$191.94M
Profit margin: 0.00%
Shares Outstanding: 93.50M

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 444.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KARD Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$191.94M	—
2024	$0.00	−$88.66M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$201.84M	−$191.94M	—
2024	$0.00	—	−$96.66M	−$88.66M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KARD Valuation vs Biotechnology Median

Median of 654 stocks

Metric	KARD	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kardigan, Inc. (KARD) is capitalised at $1.95B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 241.

KARD last closed at $20.85 on September 4, 2026. That is +$0.11 (+0.53%) against the previous close. The 52-week range on file runs from $16.25 to $27.00. The latest close sits 28.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $191.94M. Profit margin runs at 0%. Trailing earnings per share are −3.09.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for KARD.

2026 is still running; the price is −5.23% year to date.

Peer Comparison

Kardigan, Inc. (KARD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kardigan, Inc.	KARD	$1.95B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	31.8
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	39.4

The Biotechnology industry average P/E ratio is 12.9x. Kardigan, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Kardigan, Inc.

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Visit website →